Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Hepatitis C | Research article

The distribution of hepatitis C virus infection in Shanghai, China: a time-spatial study

Authors: Ling-Xiao Qu, Yang Shi, Kai-Yun Chen, Yi-Han Lu, Hong Ren

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

Shanghai, as a pilot city of China to achieve the goal of eliminating hepatitis C, its strategy of allocating medical resources is a pressing problem to be solved. This study aims to infer the time-spatial clustering patterns of HCV-infected cases, and grasp the dynamic genotype distribution of HCV, thereby inform elimination strategies of HCV with efficacy and efficiency.

Methods

Reported HCV cases including their demographic information in Shanghai city from 2005 to 2018 were released from the National Infectious Disease Reporting Information System, population data at community scale, geographical layers of hospitals, communities and districts were gathered from former research. Blood samples of HCV-infected individuals were collected during 2014–2018 from 24 sentinel hospitals, HCV-antibody test, qualitative nucleic acid test and NS5B/5’UTR gene amplification were performed accordingly to determine the genotypes of the specimen. Furthermore, global and local spatial self-correlation analysis of both acute and chronic HCV infections were conducted at community scale year by year, then time-spatial clusters of acute and chronic HCV infections and HCV genotype distribution of specimen collected from sentinel hospitals by districts were mapped by using Arcmap10.1.

Results

A total of 2631 acute HCV cases and 15,063 chronic HCV cases were reported in Shanghai from 2005 to 2018, with a peak in 2010 and 2017, respectively. The mean age of chronic HCV patients was 49.70 ± 14.55 years, 3.34 ± 0.32 years older than the acute (t = 10.55, P-value < 0.01). The spatial distribution of acute HCV infection formed one primary cluster (Relative Risk = 2.71), and the chronic formed one primary cluster and three secondary clusters with Relative Risk ranged from 1.94 to 14.42, meanwhile, an overlap of 34 communities between acute and chronic HCV clusters were found with time period spans varied from 6 to 12 years. Genotype 1 (N = 257, 49.71%) was the most prevalent HCV genotype in Shanghai, genotype 3 infections have increased in recent years. Baoshan district presented cluster of acute HCV and the highest proportion of genotype 2, Pudong new area was the cluster of chronic HCV and occupied the highest proportion of genotype 3.

Conclusions

Despite the low prevalence of HCV infection, it is still needed to push forward the elimination process in Shanghai, as there is a certain amount of HCV infected people waiting to be treated. The time-spatial clustering patterns and the dynamic of HCV genotype distribution together indicated a changing constitution of different transmission routes of HCV infection, thus, a focused strategy may be needed for high-risk population related to genotype 3 infection like drug users, in addition to an enforcement of the existing measures of preventing the iatrogenic and hematogenic transmission of HCV.
Literature
9.
go back to reference Chen YS, Li L, Cui FQ, Xing WG, Wang L, Jia ZY, et al. A sero-epidemiological study on hepatitis C in China. Chin J Epidemiol. 2011;32(9):888–91. Chen YS, Li L, Cui FQ, Xing WG, Wang L, Jia ZY, et al. A sero-epidemiological study on hepatitis C in China. Chin J Epidemiol. 2011;32(9):888–91.
12.
go back to reference National Health and Family Planning Commission, National Development and Reform Commission, Ministry of Education, Ministry of Science and Technology, Ministry of Industry and Information Technology, Ministry of Public Security, et al. Action plan for the prevention and treatment of viral hepatitis in China (2017–2020). Chin J Viral Dis. 2018; 8(01):1–5. https://doi.org/10.16505/j.2095-0136.2018.0001(Chinese.) National Health and Family Planning Commission, National Development and Reform Commission, Ministry of Education, Ministry of Science and Technology, Ministry of Industry and Information Technology, Ministry of Public Security, et al. Action plan for the prevention and treatment of viral hepatitis in China (2017–2020). Chin J Viral Dis. 2018; 8(01):1–5. https://​doi.​org/​10.​16505/​j.​2095-0136.​2018.​0001(Chinese.)
22.
go back to reference Ministry of Health of the People’s Republic of China. WS 213–2008 Diagnosis of hepatitis C (Chinese). Ministry of Health of the People’s Republic of China. WS 213–2008 Diagnosis of hepatitis C (Chinese).
23.
go back to reference National Health and Planning Commission of the People's Republic of China. WS 213–2018 Diagnosis of hepatitis C. J Clin Hepatol, 2018; (8):1619–1621. (Chinese). National Health and Planning Commission of the People's Republic of China. WS 213–2018 Diagnosis of hepatitis C. J Clin Hepatol, 2018; (8):1619–1621. (Chinese).
24.
go back to reference National Health and Planning Commission of the People's Republic of China. Screening and management of viral hepatitis C: WS/T 453–2014; 2014 (Chinese). National Health and Planning Commission of the People's Republic of China. Screening and management of viral hepatitis C: WS/T 453–2014; 2014 (Chinese).
Metadata
Title
The distribution of hepatitis C virus infection in Shanghai, China: a time-spatial study
Authors
Ling-Xiao Qu
Yang Shi
Kai-Yun Chen
Yi-Han Lu
Hong Ren
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Hepatitis C
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06577-8

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.